Jove
Visualize
Contact Us

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C virus and HIV transmission: parenteral (including percutaneous) routes are still relevant and must receive due attention.

Frontiers in public health·2026
Same author

Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study.

Southern African journal of infectious diseases·2024
Same author

Acute liver failure in low-income and middle-income countries.

The lancet. Gastroenterology & hepatology·2023
Same author

Chronic liver diseases must be reduced worldwide: it is time to act.

The Lancet. Global health·2022
Same author

Prevalence of liver fibrosis using transient elastography in the general population in Cambodia: a pilot study.

European journal of gastroenterology & hepatology·2021
Same author

Case Report: First Two Identified Cases of Fabry Disease in Central Asia.

Frontiers in genetics·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 23, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Liver diseases in developing countries.

Francesca Cainelli1

  • 1Francesca Cainelli, School of Medicine, Faculty of Health Sciences, University of Botswana, PO Box 00713, Gaborone, Botswana.

World Journal of Hepatology
|April 11, 2012
PubMed
Summary

Liver diseases pose a significant burden in low-income countries. This review highlights key liver conditions, knowledge gaps, and proposes solutions for diagnosis and management in developing nations.

Keywords:
CirrhosisDeveloping countriesHepatitisHepatocellular carcinomaLiver diseases

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Related Experiment Videos

Last Updated: May 23, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies
09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

Area of Science:

  • Hepatology
  • Global Health
  • Infectious Diseases

Background:

  • Liver diseases represent a major, under-recognized health challenge, particularly in low and middle-income countries (LMICs).
  • The highest burden of liver disease globally resides in LMICs, necessitating focused attention and research.
  • Existing research often overlooks the specific challenges faced by LMICs regarding liver health.

Purpose of the Study:

  • To provide an expert review of prevalent liver diseases in LMICs.
  • To identify critical knowledge gaps in the diagnosis and management of liver conditions in these regions.
  • To propose actionable solutions for improving liver disease care in developing countries.

Main Methods:

  • Expert review of current literature and clinical practice concerning liver diseases in LMICs.
  • Analysis of data pertaining to hepatitis B, hepatitis E, alcoholic liver disease, HIV-associated liver disease, and hepatocellular carcinoma.
  • Identification of challenges and formulation of recommendations for diagnosis and management.

Main Results:

  • Key liver diseases discussed include hepatitis B and E, alcoholic liver disease, HIV-related hepatic conditions, and hepatocellular carcinoma.
  • Significant gaps in knowledge regarding epidemiology, diagnosis, and treatment efficacy were identified.
  • Feasible strategies for improving diagnostic capabilities and management protocols were suggested.

Conclusions:

  • Addressing the burden of liver disease in LMICs requires targeted research and improved healthcare infrastructure.
  • Bridging knowledge gaps is crucial for effective prevention, diagnosis, and treatment of liver diseases.
  • Implementing suggested solutions can enhance patient outcomes and reduce the impact of liver disease in developing nations.